Skip to content
MarketScale
‹ Back to IndustriesHealthcare

The Healthcare Workforce Shortage Persists. Experts Say the True Solution is Improved, Well-Funded Schooling

Thanks to pandemic-induced burnout, an aging population placing more demand on the nation’s healthcare system, and a gap between billions in federal funding and improvements to the healthcare labor supply, the United States is witnessing a persisting healthcare workforce shortage. The shortage of physicians is expected to reach alarming levels by 2034 (perhaps as high…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

Thanks to pandemic-induced burnout, an aging population placing more demand on the nation’s healthcare system, and a gap between billions in federal funding and improvements to the healthcare labor supply, the United States is witnessing a persisting healthcare workforce shortage.

The shortage of physicians is expected to reach alarming levels by 2034 (perhaps as high as 124,000, according to one study). And a growing shortage of nurses will make this problem worse; according to estimates, we can only address this shortage by adding 1.2 million registered nurses to the workforce by 2030.

What’s both encouraging and disappointing is that the lack of trained, healthcare personnel isn’t due to a lack of interest; the healthcare training ecosystem can create some self-inflicted wounds. It’s not news that there are only a limited number of slots at nursing schools, but in 2021, as many as 92,000 qualified students were rejected from nursing schools due to a shortage of faculty and training sites.

While hospital systems are trying a variety of strategies to counteract the healthcare workforce shortage, short-term solutions that are community-specific can clearly only go so far, considering the shortage has persisted as long as it has. Roy Bejarano, CEO of Scale Healthcare, which partners with management teams across the country to improve management performance in the healthcare industry, highlights the importance of examining — and improving — the medical and nursing school system in order to deal with this persisting shortage of healthcare workers.

Roy’s Thoughts:

“Unfortunately, emergency short-term staffing solutions are often unsustainable, highly expensive transitory relationships. Hospitals would prefer stable workforces that buy into culture and quality, dependable staff that go above and beyond because they’re emotionally invested in the institution. We run the risk of too much volatility affecting care and patient outcomes.

Shortages in any area, either administrative or clinical, create pressure on those that remain, those staff members that remain, and it can become a vicious cycle all the way down, as retention becomes more difficult and as turnover increases. The good news: the problems listed in the question don’t all actually historically lead to staff shortages. Some actually are associated with increased supply of staff.

A recession, per se, should create more labor supply and lower the costs of labor, as existing workers unfortunately lose their positions and look for new employment. Healthcare is, historically, a defensive industry and it typically offers employment where other industries slow down.

A good comparison would be the tech space, venture capital, which right now, is looking at the depression. A shrinking workforce is therefore transitory. Workforces, and workforce participation goes up.

64-65% of the populace goes down 62-61%. It’s not permanent — at least historically it hasn’t been. Change and stress forces hospitals to reexamine everything that they do to find better solutions.

A plan B, contingency plans for hiring, invest more in what they have, their loyal staff, their retention. It’s not there for all bad news. There are silver linings to every crisis, and these health systems will come back.

Those that survive [will] come back stronger for it. A more important question that we should ask ourselves, is what can we do that is structurally different to get a different labor shortage outcome in healthcare the next time around? What’s going on with this recurring theme of insufficient supply in healthcare?

And I think for that, we all need to take a closer look at our schooling system. How many schools do we have? How well funded are they?

What’s their commitment to producing higher quantities of qualified clinicians? Why is the industry seemingly so excited to restrict supply?

A cynic might point to higher compensation levels for those that are there today. But what benefits one might not benefit all. Shorter training periods, other ways of allocating clinical tasks more efficiently, introducing mid-levels allowing for nurse practitioners to be more available to do more tasks versus less, less reliance on this small pocket of super well-trained, very short supply clinicians, would be probably a step in the right direction, but all of these changes take time and require a lot of analysis and collaboration.”

Article written by Aarushi Maheshwari.

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly has broken ground on a $6.5 billion manufacturing facility in Houston, slated for completion around 2030. While attention has focused on scaling production of Foundayo, its oral GLP-1 treatment, the project also reflects broader U.S. efforts to rebuild domestic pharmaceutical manufacturing and highlights the supply chain challenge of forecasting demand and building capacity years in advance.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain, making it difficult to commit billions to manufacturing capacity years before demand and required output are clear.
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

NextGen Invent’s Deepak Mittal argues for scoped healthcare AI pilots with early governance

NextGen Invent’s Deepak Mittal argues that healthcare AI pilots can begin with a reliable data subset and early governance. His performance figures are vendor claims, not independently verified results.

  • 01Deepak Mittal advocates starting with a defined problem and suitable data rather than waiting for perfect organization-wide data.
  • 02Some performance figures cited in the interview (for example, preparation time and model counts) are company-reported and not independently verified in this article.
  • 03NIST’s voluntary AI Risk Management Framework provides an independent structure for governance and risk evaluation.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512